Get notified when MAIA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Litigation (new) — Former underwriter filed breach of contract lawsuit in April 2026 claiming right of first refusal violation on March 2026 offering.
- Delisting (removed) — Detailed NYSE American delisting risk disclosure removed after previously disclosing equity deficiency and compliance via alternate standards.
MAIA raises $33M, removes going-concern warning, but faces $2.3M lawsuit over offering
Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~1 min read
Key Changes
-
high
Former underwriter H.C. Wainwright sued MAIA in April 2026 for $2.3M cash plus warrants for 1.5M shares, claiming breach of right of first refusal on the March 2026 offering that raised $33M.
Legal Proceedings verify on EDGAR → -
high
Company removed going-concern warning after March 2026 capital raise, stating the $33M will fully fund Phase 3 trial through completion with regulatory filing expected in 2027.
MD&A: Liquidity verify on EDGAR → -
high
Eight patients in Phase 2 trial achieved overall survival beyond two years without subsequent therapy, presented at European Lung Cancer Congress in March 2026.
MD&A: Clinical Results verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade MAIA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify